Skip to main content
LYSOGENE logo

LYSOGENE — Investor Relations & Filings

Ticker · LYS ISIN · FR0013233475 LEI · 969500T64RILK1RD0852 PA Professional, scientific and technical activities
Open in API
Filings indexed 254 across all filing types
Latest filing 2017-05-16 Board/Management Inform…
Country FR France
Listing PA LYS

About LYSOGENE

https://www.lysogene.com

Lysogene was a clinical-stage biotechnology company that specialized in the research and development of gene therapies for rare, inherited neurodegenerative diseases affecting the central nervous system (CNS). The company's approach focused on delivering a functional copy of a deficient gene directly to the brain to address the root cause of the targeted disorder. Its pipeline included investigational treatments for lysosomal storage diseases such as Sanfilippo syndrome type A (MPS IIIA) and GM1 gangliosidosis. Following clinical and financial challenges, the company initiated judicial liquidation proceedings in 2023.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
Board/Management Information Classification · 1% confidence The document is a press release announcing the nomination of Philippe Mendels-Flandre as Chief Operating Officer and a member of the Board of Directors. This type of announcement, detailing changes in senior management or the board, directly corresponds to the definition of Board/Management Information.
2017-05-16 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Board/Management Information Classification · 1% confidence The document is a press release announcing the recruitment of Philippe Mendels-Flandre as the new Chief Operating Officer (COO) and detailing his responsibilities and background. This type of announcement directly concerns changes in the company's senior management team. Based on the provided definitions, this aligns perfectly with the 'Board/Management Information' category (Code: MANG). The document length (3252 chars) is not indicative of a full report, and the content is purely personnel-related news.
2017-05-16 French
Rapport financier annuel
Annual Report Classification · 1% confidence The document is titled 'RAPPORT FINANCIER ANNUEL' (Annual Financial Report) for the fiscal year ending December 31, 2016. It contains comprehensive financial statements, management reports, governance reports, and auditor reports. It is a full annual report, not an announcement or a summary, and therefore fits the definition of a 10-K (Annual Report). FY 2016
2017-04-21 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is explicitly labeled as a "Press Release" dated April 20th, 2017. It announces a specific operational decision by the company (Lysogene) regarding the selection of a medical device (MRI Interventions' SmartFlow® Cannula) for an upcoming clinical trial (Phase II/III in MPS IIIA). This type of announcement, detailing operational progress, partnerships, or key study decisions outside of mandatory financial reporting periods (like 10-K or ER), typically falls under general corporate news or regulatory updates. Since it is not a financial report (10-K, IR, ER), a management change (MANG), or a specific shareholder action (DIV, DVA), it is best classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were structured as slides, but given the press release format announcing progress, RNS is the most appropriate general category for non-standard, material corporate news that doesn't fit the other specific codes. It is not a Report Publication Announcement (RPA) because it is announcing an event/decision, not the publication of a formal report itself.
2017-04-20 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is titled "Communiqué de Presse" (Press Release) and announces a specific operational decision by Lysogene: selecting the SmartFlow® cannula from MRI Interventions for an upcoming Phase II/III clinical study for MPS IIIA. It details the rationale (preclinical data) and includes quotes from management. This is a corporate announcement regarding business operations and clinical development progress, not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). Since it is a press release announcing a specific operational/clinical development milestone, it fits best under the general category of corporate news or regulatory filings that don't fit elsewhere. Given the options, it is a general corporate announcement. It is not a Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP). It is most closely aligned with a general regulatory announcement or corporate news item. Since it is a press release announcing a partnership/selection for a clinical trial, and there isn't a specific 'Clinical Update' code, 'RNS' (Regulatory Filings / General regulatory announcements) serves as the most appropriate fallback for significant, non-financial, non-management change corporate news that is publicly disseminated.
2017-04-20 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Earnings Release Classification · 1% confidence The document is titled "Communiqué de Presse" (Press Release) and explicitly states it is publishing the "information financière du premier trimestre 2017" (first quarter 2017 financial information) and the "situation de trésorerie au 31 mars 2017" (cash position as of March 31, 2017). This content—key financial highlights (cash balance, no revenue) and recent corporate events for a specific interim period—is characteristic of an Earnings Release (ER). It is not the comprehensive Interim Report (IR) itself, nor is it a full Annual Report (10-K). Given its nature as an initial announcement of period results, ER is the most appropriate classification. The document length (4103 chars) is short, but it contains the core results, making it an ER rather than just an RPA announcing the ER. Q1 2017
2017-04-12 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.